In vitro dorsal root ganglia and human prostate cell line interaction: Redefining perineural invasion in prostate cancer

The Prostate ◽  
2001 ◽  
Vol 49 (3) ◽  
pp. 213-223 ◽  
Author(s):  
Gustavo E. Ayala ◽  
Thomas M. Wheeler ◽  
H. David Shine ◽  
Monika Schmelz ◽  
Ana Frolov ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Line ◽  
Dorsal Root Ganglia ◽  
Dorsal Root ◽  
Perineural Invasion ◽  
Human Prostate ◽  
Prostate Cell ◽  
Prostate Cell Line

scholarly journals Furanoditerpenes from Pterodon pubescens benth with selective in vitro anticancer activity for prostate cell line

2009 ◽  
Vol 20 (3) ◽  
pp. 569-575 ◽  
Author(s):  
Humberto M. Spindola ◽  
João E. de Carvalho ◽  
Ana Lúcia T. G. Ruiz ◽  
Rodney A. F. Rodrigues ◽  
Carina Denny ◽  
...  
Keyword(s):  
Anticancer Activity ◽  
Cell Line ◽  
Prostate Cell ◽  
Prostate Cell Line

Cerebellar Degeneration-Related Autoantigen 1 (CDR1) Gene Expression in Prostate Cancer Cell Lines

2014 ◽  
Vol 29 (3) ◽  
pp. 288-290 ◽  
Author(s):  
Michele Salemi ◽  
Filippo Fraggetta ◽  
Antonio Galia ◽  
Pietro Pepe ◽  
Laura Cimino ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Line ◽  
Cell Lines ◽  
Cancer Cell ◽  
Cancer Cell Lines ◽  
Cerebellar Degeneration ◽  
Normal Prostate ◽  
Prostate Cell ◽  
Prostate Cell Line ◽  
Normal Prostate Cell

Prostate cancer (PCa) is the most frequent cancer among men in many developing countries, and the second leading cause of cancer-related death in men. A genetic component has been implicated in PCa onset and development. The cerebellar degeneration-related autoantigen 1 ( CDR1) gene, mapping in Xq26-q27.2, is expressed in cerebrum, cerebellum, heart, lung, liver, and kidney. In addition, CDR1 expression has been detected in neuroblastoma, renal carcinoma cell lines, and other cancer cell lines. In this study, we investigated the expression of the CDR1 gene in the LNCaP and PC-3 PCa cell lines, and in the PNT1A normal prostate cell line. CDR1 mRNA expression was evaluated by qRT-PCR. We found that the CDR1 gene was overexpressed in the LNCaP and PC-3 PCa cell lines as compared with the PNT1A normal prostate cell line. These data suggest that CDR1 could be a new biomarker for PCa identification.

scholarly journals Studies on the Cytotoxic Activities of Punica granatum L. var. spinosa (Apple Punice) Extract on Prostate Cell Line by Induction of Apoptosis

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Koushan Sineh Sepehr ◽  
Behzad Baradaran ◽  
Masoumeh Mazandarani ◽  
Vahid Khori ◽  
Fatemeh Zare Shahneh
Keyword(s):  
Cell Proliferation ◽  
Cell Line ◽  
Cell Lines ◽  
Punica Granatum ◽  
Human Prostate ◽  
Cytotoxic Activities ◽  
Antitumor Effects ◽  
Prostate Cell ◽  
Prostate Cell Line ◽  
Induction Of Apoptosis

The Punica granatum L. var. granatum (pomegranate) has been demonstrated to exert antitumor effects on various types of cancer cells. The present study aimed to evaluate the medicinal herbs Punica granatum L. var. spinosa (apple punice) that are native to Iran. This study was determined to test the possible cytotoxic activity and induction of apoptosis on human prostate cell lines. The effect of ethanol extracts of the herbs on the inhibition of cell proliferation was assessed by MTT colorimetric assay. PC3 cell lines treated with the extracts were analyzed for the induction of apoptosis by cell death detection (ELISA) and TUNEL assay. Dye exclusion analysis was performed for viability rate. Our results demonstrated that the Punica granatum L. var. spinosa extract dose dependently suppressed the proliferation of PC3 cells (IC50= 250.21 μg/mL) when compared with a chemotherapeutic anticancer drug (Toxol) (Vesper Pharmaceuticals) with increased nucleosome production from apoptotic cells. The Punica granatum L. var. spinosa extract attenuated the human prostate cell proliferation in vitro possibly by inducing apoptosis. The Punica granatum L. var. spinosa is likely to be valuable for the treatment of some forms of human prostate cell line.

Growth Attenuation in a Human Prostate Cell Line Mediated by a Phorbol Ester

1995 ◽  
Vol 209 (2) ◽  
pp. 152-156 ◽  
Author(s):  
N. Novichenko ◽  
S. Konno ◽  
Y. Nakajima ◽  
T. C. Hsieh ◽  
W. X. K. Turo ◽  
...  
Keyword(s):  
Cell Line ◽  
Phorbol Ester ◽  
Human Prostate ◽  
Prostate Cell ◽  
Prostate Cell Line

USP2a is an oncogenic isopeptidase and a potential target in prostate cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14522-14522
Author(s):  
C. Priolo ◽  
D. Tang ◽  
M. Brahmandam ◽  
B. Benassi ◽  
E. Sicinska ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Nude Mice ◽  
Fatty Acid Synthase ◽  
Chemotherapeutic Agents ◽  
Human Prostate ◽  
Wild Type ◽  
Normal Prostate ◽  
Prostate Cell

14522 Background: De-ubiquitinating enzymes (isopeptidases) remove ubiquitin side chains prior to degradation by the proteosome thus stabilizing their protein targets. We have identified a novel androgen regulated isopeptidase, USP2a, and demonstrated that it binds and prolongs the half-life of fatty acid synthase (FAS), a key enzyme in lipid metabolism of tumor cells. Methods: We determined whether USP2a has oncogenic properties in vitro and in vivo. Wild-type and catalytically inactive USP2a were introduced in immortalized normal prostate epithelial cells (AR-iPrECs). Clonogenicity assays and apoptosis induction by chemotherapeutic agents were performed on these cells. Anti-USP2a siRNA were transfected in normal and transformed (LNCaP, DU145 and PC-3) prostate cell lines. Oncogenicity in vivo was shown by s.c. injection of NIH3T3-USP2a cells in nude mice. Furthermore, USP2a mRNA expression and gene microarrays were tested in 52 human prostate adenocarcinomas. Results: Wild-type USP2a overexpression in AR-iPrEC cells resulted in a significant increase in number and size of colonies compared to those obtained in parental cells. Growth in soft agar was significantly enhanced as well. Silencing of USP2a in LNCAP and DU145 cells resulted in a strong apoptotic effect, evaluated by FACS analysis and cleaved-PARP expression. The role of this isopeptidase in apoptosis regulation was confirmed on AR-iPrEC-USP2a cells, that showed resistance to apoptosis induced by cisplatin and taxol. Importantly, USP2a overexpression was able to transform NIH3T3 cells, generating greater than or equal to 0.5 cm subcutaneous tumors in 12/12 nude mice within 3 weeks, while none of the negative controls grew. USP2a mRNA was overexpressed in 39% of human prostate cancers, showing 1.6–104 (median 5.48) fold induction relative to normal tissues by qRT-PCR. Gene expression profiling of the same tumors revealed specific signatures in USP2a-overexpressing tumors. Conclusions: Our results demonstrate that USP2a behaves as an oncogene in vitro and in vivo and is overexpressed in organ-confined prostate cancer. These data strongly suggest that this isopeptidase is a potential drug target in prostate cancer. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document